Les renseignements du Formulaire de médicaments s’adressent aux professionnels de la santé. Il ne s’agit pas d’un avis médical. Certains des renseignements, y compris ceux sur le financement des médicaments anticancéreux, ne s’appliquent pas à tous les patients. Les plans de traitement du cancer sont propres à chaque patient. Si vous êtes un patient, veuillez parler avec votre équipe soignante pour comprendre comment ces renseignements s’appliquent à vous.
BEP(5D)
Curative
(Adjuvant- In clinical stage 1 non-seminomatous testicular cancer, may be used as adjuvant treatment for patients who are unsuitable for primary surveillance, or who prefer immediate treatment.)
Regimen is considered appropriate as part of the standard care of patients; meaningfully improves outcomes (survival, quality of life), tolerability or costs compared to alternatives (recommended by the Disease Site Team and national consensus body e.g. pan-Canadian Oncology Drug Review, pCODR). Recommendation is based on an appropriately conducted phase III clinical trial relevant to the Canadian context OR (where phase III trials are not feasible) an appropriately sized phase II trial. Regimens where one or more drugs are not approved by Health Canada for any indication will be identified under Rationale and Use.
Treatment of patients with non-seminomatous testicular cancer
REPEAT EVERY 21 DAYS
For a usual total of 3 to 4 cycles (adjuvant setting: Up to 2 cycles)
High (D1-5)
Minimal (D8, 15)
High
Other Supportive Care:
- Premedication may be given to prevent hypersensitivity reactions. (e.g.- hydrocortisone IV and/or diphenhydramine, and optional acetaminophen)
• Standard regimens for Cisplatin premedication and hydration should be followed. Refer to local guidelines
- Fertility counselling and sperm bank should be routinely offered.
• Also refer to CCO Antiemetic Recommendations.
Doses should be modified according to the protocol by which the patient is being treated. As dose modification of BEP treatment may compromise its efficacy, it is recommended that modification of this regimen be done only after discussion with a medical oncologist experienced in the treatment of testicular cancer. Therefore, specific recommendations are not provided.
Most frequently occurring adverse effects:
- Nausea and vomiting
- Nephrotoxicity
- Neurotoxicity (ototoxicity)
- Myelosuppression
- Stomatitis and diarrhea
- Skin changes and increased pigmentation
- Fevers (hypersensitivity)
- Pulmonary toxicity with Bleomycin at doses > 500 U
- Alopecia
- Infertility
- Fatigue
Recommended Clinical Monitoring
- Clinical toxicity assessment (including local toxicity, neurotoxicity, ototoxicity, pulmonary).
- CBC before each cycle. Interim counts should be done in first cycle and repeated if dose modifications necessary.
- Chest x-ray before each cycle.
- Baseline and regular liver and renal function tests (including electrolytes and magnesium), and urinalysis.
- Routine pulmonary function test, if more than 9 weeks of Bleomycin treatment is planned.
- Grade toxicity using the current NCI-CTCAE (Common Terminology Criteria for Adverse Events) version
back to top
Einhorn LH, Williams SD, Chemotherapy of disseminated testicular cancer. Cancer, 1980; 46: 1339-1344.
Williams SD, Birch R, Einhorn LH et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med, 1987; 316: 1435-1440.
de Wit R, Roberts T, Wilkinson PM et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5- day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for research and treatment of cancer genitourinary tract cancer cooperative group and the Medical Research Council. J of Clinical Oncology 2001, March 15; 19(6); 1629-40.
Williams S, Birch R, Einhorn LH et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med, 1987; 316: 1435-144.
Regimen Abstracts
A Regimen Abstract is an abbreviated version of a Regimen Monograph and contains only top level information on usage, dosing, schedule, cycle length and special notes (if available). It is intended for healthcare providers and is to be used for informational purposes only. It is not intended to constitute or be a substitute for medical advice, and all uses of the Regimen Abstract are subject to clinical judgment. Such information is provided on an “as-is” basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information’s quality, accuracy, currency, completeness, or reliability, and Cancer Care Ontario disclaims all liability for the use of this information, and for any claims, actions, demands or suits that arise from such use.
Information in regimen abstracts is accurate to the extent of the ST-QBP regimen master listings, and has not undergone the full review process of a regimen monograph. Full regimen monographs will be published for each ST-QBP regimen as they are developed.
Regimen Monographs
Refer to the New Drug Funding Program or Ontario Public Drug Programs websites for the most up-to-date public funding information.
The information set out in the drug monographs, regimen monographs, appendices and symptom management information (for health professionals) contained in the Drug Formulary (the "Formulary") is intended for healthcare providers and is to be used for informational purposes only. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects of a particular drug, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for a given condition. The information in the Formulary is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. All uses of the Formulary are subject to clinical judgment and actual prescribing patterns may not follow the information provided in the Formulary.
The format and content of the drug monographs, regimen monographs, appendices and symptom management information contained in the Formulary will change as they are reviewed and revised on a periodic basis. The date of last revision will be visible on each page of the monograph and regimen. Since standards of usage are constantly evolving, it is advised that the Formulary not be used as the sole source of information. It is strongly recommended that original references or product monograph be consulted prior to using a chemotherapy regimen for the first time.
Some Formulary documents, such as the medication information sheets, regimen information sheets and symptom management information (for patients), are intended for patients. Patients should always consult with their healthcare provider if they have questions regarding any information set out in the Formulary documents.
While care has been taken in the preparation of the information contained in the Formulary, such information is provided on an “as-is” basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information’s quality, accuracy, currency, completeness, or reliability.
CCO and the Formulary’s content providers shall have no liability, whether direct, indirect, consequential, contingent, special, or incidental, related to or arising from the information in the Formulary or its use thereof, whether based on breach of contract or tort (including negligence), and even if advised of the possibility thereof. Anyone using the information in the Formulary does so at his or her own risk, and by using such information, agrees to indemnify CCO and its content providers from any and all liability, loss, damages, costs and expenses (including legal fees and expenses) arising from such person’s use of the information in the Formulary.